This week's FierceBiotech is brought to you by IQVIA.

Trouble viewing? Click here.

IQVIA
IQVIA Virtual Trials IQVIA
IQVIA
In a recent Phase III Type I diabetes trial, IQVIA faced aggressive timelines to meet a submission deadline. IQVIA accelerated site identification and patient recruitment to help our customer meet the critical regulatory filing dates.

IQVIA Core-Powered Clinical Development
Our CORE-powered approach to clinical development dramatically increases speed and efficiency to help you bring your products to patients faster.
  • Accelerate site identification by up to 40%
  • Increase patient enrollment by up to 30%
  • Applied to more than 200 clinical studies
Proof, not promises
Data based on a recent Phase III Type I diabetes trial. Comparisons based on previous studies in the same indication and geographies conducted by IQVIA. Results may vary due to various factors.

Want to reach 137,000+ FierceBiotech subscribers with your own message?
Contact aalcover@fiercemarkets.com or call 202-824-5074.



You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from FierceBiotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

FierceMarkets, a division of Questex, LLC
1900 L St. NW Suite 400 
Washington, DC 20036